| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.3M | — | +27.2% |
| R&D Expense | $726K | — | -38.8% |
| SG&A Expense | $3.9M | — | +9.8% |
| Operating Income | -$118K | — | +94.7% |
| Pre-tax Income | $713K | — | +142.3% |
| Income Tax | $125K | — | +400.0% |
| Net Income | $588K | — | +134.4% |
| EPS (Basic) | $0.03 | — | +133.3% |
| EPS (Diluted) | $0.03 | — | +133.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $59.2M | -15.4% | +21.7% |
| Accounts Receivable | $28.8M | +15.0% | +24.2% |
| Inventory | $13.2M | -11.0% | -39.8% |
| Current Assets | $121.1M | +2.8% | -0.4% |
| Total Assets | $154.6M | +2.0% | +2.1% |
| Current Liabilities | $19.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.3M | — | -546.8% |
| Capital Expenditures | $2.6M | — | +125.3% |
| Investing Cash Flow | -$2.4M | — | -324.1% |
| Financing Cash Flow | -$114K | — | +29.6% |
| Free Cash Flow | -$10.8M | — | -347.2% |
| +48.4% |
| Total Liabilities | $23.0M | +12.3% | +69.1% |
| Stockholders' Equity | $131.5M | +0.4% | -4.6% |